Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>M Stanley Expects JD HEALTH (06618.HK) to Maintain Strong Growth This Yr, but NP May Be Flattish
Recommend 6 Positive 4 Negative 0 |
||||
|
||||
|
JD HEALTH (06618.HK) announced its annual results for the year ended December 2025, with 4Q25 revenue growing 27% YoY, 4% above market consensus, according to Morgan Stanley's research report. Adjusted operating profit surged by 246% YoY, in line with expectation. Adjusted net profit rose by 30%, beating other income, but it is expected that net profit may be flattish this year. Therefore, the broker rated the Group at Equalweight, with a target price of $70. The Company's management believed that its moat is widening compared to its peers across categories, especially for pharmaceutical products with strict fulfillment standards. The management also denied any intention to make large-scale M&As for offline facilities, which should alleviate investor concerns about equity dilution and integration risks. AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
